Recent blog posts
GRIN3B Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, NMDA 3B Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GRIN3B Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, NMDA 3B Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GRIN3B protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MED14 Biologics Sequence Review Report 2026: Mediator of RNA polymerase II transcription subunit 14 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MED14 Biologics Sequence Review Report 2026: Mediator of RNA polymerase II transcription subunit 14 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of MED14 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
EFNA2 Biologics Sequence Review Report 2026: Ephrin-A2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
EFNA2 Biologics Sequence Review Report 2026: Ephrin-A2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of EFNA2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CYTH3 Biologics Sequence Review Report 2026: Cytohesin-3 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CYTH3 Biologics Sequence Review Report 2026: Cytohesin-3 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CYTH3 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
HCRTR1 Biologics Sequence Review Report 2026: Orexin/Hypocretin receptor type 1 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
HCRTR1 Biologics Sequence Review Report 2026: Orexin/Hypocretin receptor type 1 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of HCRTR1 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GALR2 Biologics Sequence Review Report 2026: Galanin receptor type 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GALR2 Biologics Sequence Review Report 2026: Galanin receptor type 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GALR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GRID2 Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, delta-2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GRID2 Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, delta-2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GRID2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MLNR Biologics Sequence Review Report 2026: Motilin receptor Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MLNR Biologics Sequence Review Report 2026: Motilin receptor Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of MLNR protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FFAR2 Biologics Sequence Review Report 2026: Free fatty acid receptor 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FFAR2 Biologics Sequence Review Report 2026: Free fatty acid receptor 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FFAR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
P2RX6 Biologics Sequence Review Report 2026: P2X purinoceptor 6 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
P2RX6 Biologics Sequence Review Report 2026: P2X purinoceptor 6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of P2RX6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GRIN2D Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, NMDA 2D Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GRIN2D Biologics Sequence Review Report 2026: Glutamate receptor ionotropic, NMDA 2D Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GRIN2D protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GRM6 Biologics Sequence Review Report 2026: Metabotropic glutamate receptor 6 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GRM6 Biologics Sequence Review Report 2026: Metabotropic glutamate receptor 6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GRM6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →